In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Mineralys Therapeutics Inc (NASDAQ: MLYS) closed the day trading at $16.17 down -4.15% from the previous closing price of $16.87. In other words, the price has decreased by -$4.15 from its previous closing price. On the day, 1.08 million shares were traded. MLYS stock price reached its highest trading level at $17.3438 during the session, while it also had its lowest trading level at $16.145.
Ratios:
For a better understanding of MLYS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.02 and its Current Ratio is at 14.02. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 10, 2024, initiated with a Buy rating and assigned the stock a target price of $30.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.
On March 07, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $27.Wells Fargo initiated its Overweight rating on March 07, 2023, with a $27 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 13 ’25 when Samsara BioCapital GP, LLC bought 600,000 shares for $13.50 per share. The transaction valued at 8,100,000 led to the insider holds 5,674,916 shares of the business.
AKKARAJU SRINIVAS bought 600,000 shares of MLYS for $8,100,000 on Mar 13 ’25. The Director now owns 5,674,916 shares after completing the transaction at $13.50 per share. On Mar 13 ’25, another insider, RA CAPITAL MANAGEMENT, L.P., who serves as the Director of the company, bought 1,296,296 shares for $13.50 each. As a result, the insider paid 17,499,996 and bolstered with 4,280,051 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 1015453376 and an Enterprise Value of 607655232.
Stock Price History:
The Beta on a monthly basis for MLYS is -0.41, which has changed by 0.25934577 over the last 52 weeks, in comparison to a change of 0.10838497 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $18.38, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is 47.16%, while the 200-Day Moving Average is calculated to be 32.84%.
Shares Statistics:
Over the past 3-months, MLYS traded about 797.41K shares per day on average, while over the past 10 days, MLYS traded about 1838940 shares per day. A total of 49.82M shares are outstanding, with a floating share count of 36.97M. Insiders hold about 41.12% of the company’s shares, while institutions hold 46.20% stake in the company. Shares short for MLYS as of 1740700800 were 2013841 with a Short Ratio of 2.53, compared to 1738281600 on 1862767. Therefore, it implies a Short% of Shares Outstanding of 2013841 and a Short% of Float of 5.91.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
